MedPath

Comparison of CIPA With the GLIM Criteria and Prevalence of Sarcopenia in Inpatients

Recruiting
Conditions
Malnutrition
Registration Number
NCT06031766
Lead Sponsor
University Hospital of the Nuestra Señora de Candelaria
Brief Summary

Determine the diagnostic quality of the CIPA tool, in inpatients with stays longer than three days, in the observation of risk of malnutrition compared to the gold standard GLIM as a diagnosis of malnutrition.

Detailed Description

Background: malnutrition is a poor prognostic factor in inpatients. Its early detection, together to nutritional intervention, can improve clinical evolution. It is important to carry out nutritional screening, however, there is no gold standard, and CIPA (Control of Intakes, Proteins and Anthropometry) has been implemented in our setting. The GLIM criteria (Global Leadership Initiative on Malnutrition) aim to provide a global consensus that allows common criteria for malnutrition diagnosis. The objective of this study is to evaluate the diagnostic quality of the CIPA screening vs the GLIM criteria for malnutrition as well as to establish the prevalence of sarcopenia.

Methods: cross-sectional single-center study comparing the diagnostic quality of CIPA in the diagnosis of malnutrition or risk of presenting it in inpatients vs GLIM. Adults of both sexes with a hospital stay of more than three days and attached to one of the following departments will be included: general surgery, internal medicine, vascular surgery, digestive system, hematology, nephrology, pulmonology, oncology, neurology, traumatology. The diagnostic evaluation of malnutrition and functionality will be carried out after three days of hospital stay, once the CIPA screening has been carried out. The participation of the patients in the study will consist of performing the CIPA malnutrition screening to which the GLIM test will be added. For the CIPA test, the BMI (body mass index), albumin levels and percentage of decreased intake will be taken. For the GLIM test, phenotypic criteria such as non-voluntary weight loss and reduction in muscle mass will also be studied together with etiological criteria to which, in addition to those referred to for the CIPA test, the presence of inflammation will be added. The study consists of a first cross-sectional part that will be completed once the data of the 490 subjects selected through probabilistic sampling has been collected. The second part of the study will consist of the prospective follow-up of the patients and the variables will be analyzed with prognostic criteria.

Discussion: this study will evaluate the diagnostic quality of CIPA vs the GLIM criteria for malnutrition and will establish the prevalence of sarcopenia in inpatients.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
490
Inclusion Criteria
  • Adult subjects (> 18 years old).
  • Hospital stay more than 3 days.
  • Admitted to one of the following departments: general surgery, internal medicine, vascular surgery, digestive system, hematology, nephrology, pulmonology, oncology, neurology, traumatology.
Exclusion Criteria
  • Subjects with a prognosis of hospital stay less or equal than 3 days.
  • Admitted to services with a low incidence of malnutrition: ophthalmology, dermatology or obstetrics.
  • Admitted or critical care unit and palliative care.
  • Pediatric patient.
  • Patients treated with nutritional support before CIPA screening is performed.
  • Patients with edema-ascitic overload.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The concordance between CIPA test and the GLIM criteria determined by the Kappa coefficient.6 months
Secondary Outcome Measures
NameTimeMethod
Incidence of mortality6 months
Incidence of readmissions6 months
Mean length of stay (days)6 months

Trial Locations

Locations (1)

UniversityHNSC

🇪🇸

Santa Cruz de Tenerife, Spain

UniversityHNSC
🇪🇸Santa Cruz de Tenerife, Spain
Elena Márquez Mesa, Physician
Contact
697232171
elenamqz@hotmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.